Targeted Next-generation Sequencing of Cancer Genes in Poorly Differentiated Thyroid Cancer

Overview

Journal Endocr Connect

Specialty Endocrinology

Date 2017 Nov 15

PMID 29133385

Citations 24

Authors

Tiemo S Gerber

Arno Schad

Nils Hartmann

Erik Springer

Ulrich Zechner

Thomas J Musholt

Affiliations

Soon will be listed here.

Abstract

Poorly differentiated thyroid carcinoma (PDTC) is a rare malignancy with higher mortality than well-differentiated thyroid carcinoma. The histological diagnosis can be difficult as well as the therapy. Improved diagnosis and new targeted therapies require knowledge of DNA sequence changes in cancer-relevant genes. The TruSeq Amplicon Cancer Panel was used to screen cancer genomes from 25 PDTC patients for somatic single-nucleotide variants in 48 genes known to represent mutational hotspots. A total of 4490 variants were found in 23 tissue samples of PDTC. Ninety-eight percent (4392) of these variants did not meet the inclusion criteria, while 98 potentially pathogenic or pathogenic variants remained after filtering. These variants were distributed over 33 genes and were all present in a heterozygous state. Five tissue samples harboured not a single variant. Predominantly, variants in (43% of tissue samples) were identified, while less frequently, variants in , , , , and (each in 17% of tissue samples) as well as , and (each in 13% of tissue samples) were observed. This study identified new potential genetic targets for further research in PDTC. Of particular interest are four observed (alias ) variants, which have not been connected to this type of thyroid carcinoma so far. In addition, and mutations have not been reported in this subtype of cancer either. In contrast to other reports, we did not find variants.

Citing Articles

Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma.

Elghawy O, Barsouk A, Xu J, Chen S, Cohen R, Sun L Eur Thyroid J. 2024; 13(6).

PMID: 39485731 PMC: 11623262. DOI: 10.1530/ETJ-24-0225.

Systemic treatments for radioiodine-refractory thyroid cancers.

Chen P, Yao Y, Tan H, Li J Front Endocrinol (Lausanne). 2024; 15:1346476.

PMID: 39473507 PMC: 11518755. DOI: 10.3389/fendo.2024.1346476.

Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Kim J, Myung J, Kim S, Tae K, Choi Y, Lee S Endocrinol Metab (Seoul). 2024; 39(4):590-602.

PMID: 38925909 PMC: 11375297. DOI: 10.3803/EnM.2024.1927.

Poorly differentiated thyroid carcinoma arising from substernal goiter: a case report.

Apelian S, Ismail S, Roumieh D, Saad B, Alshehabi Z Ann Med Surg (Lond). 2024; 86(5):3020-3024.

PMID: 38694372 PMC: 11060243. DOI: 10.1097/MS9.0000000000001868.

Current evidences in poorly differentiated thyroid carcinoma: a systematic review and subsection meta-analysis for clinical decision making.

Chatterjee S, Mair M, Shaha A, Paleri V, Sawhney S, Mishra A Endocrine. 2024; 85(2):509-519.

PMID: 38504051 DOI: 10.1007/s12020-024-03771-x.

References

Rocha A, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira M, Sobrinho-Simoes M . E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003; 42(6):580-7. DOI: 10.1046/j.1365-2559.2003.01642.x. View

Wain H, Bruford E, Lovering R, Lush M, Wright M, Povey S . Guidelines for human gene nomenclature. Genomics. 2002; 79(4):464-70. DOI: 10.1006/geno.2002.6748. View

Pilotti S, Collini P, Mariani L, Placucci M, Bongarzone I, Vigneri P . Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol. 1997; 21(12):1466-73. DOI: 10.1097/00000478-199712000-00009. View

Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R . Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics. 2012; 12(8):609-17. PMC: 3271313. DOI: 10.2174/138920211798120853. View

van Nistelrooij A, van Marion R, Koppert L, Biermann K, Spaander M, Tilanus H . Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples. BMC Res Notes. 2017; 10(1):144. PMC: 5379534. DOI: 10.1186/s13104-017-2456-5. View

Mlecnik B, Bindea G, Kirilovsky A, Angell H, Obenauf A, Tosolini M . The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016; 8(327):327ra26. DOI: 10.1126/scitranslmed.aad6352. View

Pita J, Figueiredo I, Moura M, Leite V, Cavaco B . Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014; 99(3):E497-507. DOI: 10.1210/jc.2013-1512. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Lazzereschi D, Nardi F, Turco A, Ottini L, DAmico C, Mariani-Costantini R . A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene. 2005; 24(34):5344-54. DOI: 10.1038/sj.onc.1208603. View

10.

Eloy C, Ferreira L, Salgado C, Soares P, Sobrinho-Simoes M . Poorly Differentiated and Undifferentiated Thyroid Carcinomas. Turk Patoloji Derg. 2015; 31 Suppl 1:48-59. DOI: 10.5146/tjpath.2015.01314. View

11.

Soares P, Trovisco V, Rocha A, Feijao T, Rebocho A, Fonseca E . BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004; 444(6):572-6. DOI: 10.1007/s00428-004-1018-0. View

12.

Basolo F, Pisaturo F, Pollina L, Fontanini G, Elisei R, Molinaro E . N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000; 10(1):19-23. DOI: 10.1089/thy.2000.10.19. View

13.

Tomei S, Mazzanti C, Marchetti I, Rossi L, Zavaglia K, Lessi F . c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med. 2012; 10:7. PMC: 3267663. DOI: 10.1186/1479-5876-10-7. View

14.

Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley D . Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015; 7(283):283ra53. PMC: 4442685. DOI: 10.1126/scitranslmed.aaa7161. View

15.

Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

16.

Williams C, Bernard J, Demory Beckler M, Almohazey D, Washington M, Smith J . ERBB4 is over-expressed in human colon cancer and enhances cellular transformation. Carcinogenesis. 2015; 36(7):710-8. PMC: 4572918. DOI: 10.1093/carcin/bgv049. View

17.

Xu B, Ghossein R . Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma. Endocr Pathol. 2016; 27(3):205-12. DOI: 10.1007/s12022-016-9445-4. View

18.

Grim J . Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models. Gut. 2013; 63(5):707-9. DOI: 10.1136/gutjnl-2013-305144. View

19.

Cruse G, Metcalfe D, Olivera A . Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am. 2014; 34(2):219-37. PMC: 3994404. DOI: 10.1016/j.iac.2014.01.002. View

20.

Sanders Jr E, LiVolsi V, Brierley J, Shin J, Randolph G . An evidence-based review of poorly differentiated thyroid cancer. World J Surg. 2007; 31(5):934-45. DOI: 10.1007/s00268-007-9033-3. View